natgillin/translations-raw huggingface dataset:
* Skin rash may affect more than 1 in 10 people (very common) when OLYSIO is used in combination with sofosbuvir for 24 weeks. 
- zvečana koncentracija bilirubina v krvi (bilirubin je barvilo, ki nastaja v jetrih) * Kadar se zdravilo OLYSIO v kombinaciji s sofosbuvirjem jemlje 24 tednov, se kožni izpuščaj lahko pojavi pri več kot 1 od 10 bolnikov (zelo pogosto).
No meaningful changes in QTc interval were observed with either the recommended dose of 150 mg once daily or the supratherapeutic dose of 350 mg once daily. 
150 mg enkrat na dan niti pri supraterapevtskem odmerku 350 mg enkrat na dan. Pediatrična populacija
OLYSIO in combination with peginterferon alfa and ribavirin: HCV/HIV-1 co-infected patients should be treated for the same duration as HCV mono-infected patients, except for co-infected patients with cirrhosis who should receive 36 weeks of treatment with peginterferon alfa and ribavirin after completing 12 weeks of treatment with OLYSIO, peginterferon alfa and ribavirin (total treatment duration of 48 weeks). 
Uporaba zdravila OLYSIO v kombinaciji s peginterferonom alfa in ribavirinom: bolnike s sočasno okužbo s HCV/HIV-1 je treba zdraviti enako dolgo kot bolnike, ki so okuženi samo s HCV, razen v primeru bolnikov s sočasno okužbo z obema virusoma in s cirozo: ti bolniki naj po zaključenem
Q80R3 
D168E D168V Q80R3
Genotype 4, treatment-naïve or treatment-experienced2, with compensated cirrhosis or without cirrhosis patients without cirrhosis: 8 or 12 weeks SMV + sofosbuvir; patients with cirrhosis: 
Bolniki brez ciroze: 8 ali 12 tednov SMV + sofosbuvir; Bolniki s cirozo: 12 tednov SMV + sofosbuvir
Rifampicin1 600 mg once daily rifampicin AUC 1.00 (0.93-1.08) ↔ rifampicin Cmax 0.92 (0.80-1.07) ↔ rifampicin Cmin not studied 25-desacetyl-rifampicin AUC 1.24 (1.13-1.36) ↑ 25-desacetyl-rifampicin Cmax 1.08 (0.98-1.19) ↔ 25-desacetyl-rifampicin Cmin not studied simeprevir AUC 0.52 (0.41-0.67) ↓ simeprevir Cmax 1.31 (1.03-1.66) ↑ simeprevir Cmin 0.08 (0.06-0.11) ↓ 
AUC rifampicina 1,00 (0,93-1,08) ↔ Cmax rifampicina 0,92 (0,80-1,07) ↔ Cmin rifampicina niso preučevali AUC 25-dezacetil-rifampicina 1,24 (1,13-1,36)
Co-administration of OLYSIO with ciclosporin is not recommended as this leads to significantly higher exposure of simeprevir based on interim data from an ongoing phase 2 study in HCV infected post-liver transplant patients (see section 4.5). 
Na osnovi vmesnih podatkov še potekajoče študije faze 2 pri bolnikih po presaditvi jeter, okuženih s HCV (glejte poglavje 4.5), sočasna uporaba zdravila OLYSIO s ciklosporinom ni priporočljiva, ker pomembno zveča izpostavljenost simeprevirju.
(mild to moderate CYP3A4 enzyme inhibition) 
(šibko do zmerno zaviranje CYP3A4)
(moderate CYP3A4 enzyme induction) 
(zmerna indukcija CYP3A4)
Significantly increased plasma concentrations of simeprevir are expected. 
Pričakuje se pomembno zvečanje koncentracije simeprevirja v plazmi.
Genotype 1, prior relapsers2, with compensated cirrhosis or without cirrhosis 
genotip 1, bolniki s ponovitvijo bolezni2, s kompenzirano cirozo ali brez ciroze
In HCV genotype 1a infected patients without cirrhosis, simeprevir efficacy in combination with sofosbuvir at the recommended 12-week treatment duration was not impacted by the presence of the NS3 Q80K polymorphism (see section 5.1). 
Prisotnost polimorfizma NS3 Q80K (glejte poglavje 5.1), pri bolnikih s HCV genotipa 1 brez ciroze ni vplivala na učinkovitost simeprevirja v kombinaciji s sofosbuvirjem med priporočenim 12-tedenskem zdravljenjem.
METAVIR fibrosis score 
Stopnja fibroze po klasifikaciji METAVIR F0-2
3 The dose of simeprevir in this interaction study was 50 mg when co-administered in combination with darunavir/ritonavir, compared to 150 mg in the simeprevir alone treatment group. 
Medsebojno delovanje med simeprevirjem in tem zdravilom so ocenjevali v farmakokinetični podštudiji v okviru študije faze 2 pri 22 bolnikih, okuženih s HCV. 3 V tej interakcijski študiji so 50 mg simeprevirja v kombinaciji z darunavirjem oziroma ritonavirjem primerjali s 150 mg simeprevirja samostojno.
The 167 enrolled patients had a median age of 57 years (range 27 to 70 years; with 5% above 65 years); 64% were male; 81% were White, 19% Black or African American, and 21% Hispanic; 37% had a BMI ≥ 30 kg/m2; the median baseline HCV RNA level was 6.7 log10 IU/ml; 
64% je bilo moških, 81% belcev, 19% črne rase ali afroameričanov in 21% latinskoameriške etnične skupine; 37% jih je imelo ITM ≥ 30 kg/m2; mediana izhodiščne koncentracije HCV RNK je bila 6,7 log10 i.e./ml; 75% ni imelo ciroze (ocena fibroze po klasifikaciji METAVIR F0-3), 25% jih je imelo cirozo (ocena fibroze po klasifikaciji METAVIR F4); 78% je bilo okuženih s HCV genotipa 1a,
Increased simeprevir concentrations may occur due to inhibition of OATP1B1 by atorvastatin. 
Zaradi zaviranja OATP1B1 z atorvastatinom se lahko pričakuje zvečanje koncentracij simeprevirja.
nelfinavir, nevirapine, ritonavir, saquinavir or tipranavir to treat HIV infection - atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin or simvastatin to lower cholesterol levels - ciclosporin, sirolimus or tacrolimus to lower immune response or prevent organ transplant failures - sildenafil or tadalafil to treat ‘pulmonary arterial hypertension' - midazolam or triazolam (when taken by mouth) to help you sleep or for anxiety 
- sildenafil ali tadalafil za zdravljenje pljučne arterijske hipertenzije - midazolam ali triazolam (če ju zaužijete) za zdravljenje nespečnosti ali za lajšanje tesnobe
Outcome for patients without SVR12 On-treatment failure Viral relapse1 
Rezultati zdravljenja pri bolnikih, ki niso dosegli SVR12 neuspeh v času zdravljenja ponovitev bolezni2 brez podatkov o SVR125
Mild increases in simeprevir concentrations may occur due to inhibition of CYP3A4 by amiodarone. 
Zaradi zaviranja CYP3A4 z amiodaronom lahko pride do blagega zvečanja koncentracij simeprevirja v plazmi.
tacrolimus AUC 0.83 (0.59-1.16) ↓ tacrolimus Cmax 0.76 (0.65-0.90) ↓ tacrolimus Cmin not studied simeprevir AUC 1.85 (1.18-2.91) ↑6 simeprevir Cmax 1.79 (1.22-2.62) ↑6 simeprevir Cmin not studied6 
AUC simeprevirja 1,85 (1,18-2,91) ↑6 Cmax simeprevirja 1,79 (1,22-2,62) ↑6
Outcome for patients without SVR12 On-treatment failure Viral relapse2 
SVR12 Izid zdravljenja pri bolnikih brez SVR12
Table 22: Treatment outcome in HCV genotype 1 infected patients with HIV-1 co-infection 
Preglednica 19: Izid zdravljenja pri predhodno nezdravljenih bolnikih, okuženih s HCV
1 In HCV genotype 1a infected patients with cirrhosis, testing for the presence of the Q80K polymorphism may be considered prior to initiation of therapy with OLYSIO in combination with sofosbuvir (see section 4.4). 
HCV genotipa 1a razmislite o testiranju na prisotnost polimorfizma Q80K (glejte poglavje 4.4).
3 Viral relapse rates are calculated with a denominator of patients with undetectable (or unconfirmed detectable) 
3 Pogostnost ponovitve bolezni je izračunana na podlagi imenovalca, ki predstavlja število bolnikov z nezaznavno (ali nepotrjeno zaznavno) koncentracijo HCV RNK ob dejanskem zaključku zdravljenja.
The following side effects may happen with OLYSIO when used in combination with peginterferon alfa and ribavirin: 
Pri jemanju zdravila OLYSIO skupaj s peginterferonom alfa in ribavirinom se lahko pojavijo naslednji neželeni učinki:
Increased plasma concentrations of simeprevir are expected. 
Pričakovano je zvečanje koncentracije simeprevirja v plazmi.
- digoxin, disopyramide, flecainide, mexiletine, propafenone or quinidine (when taken by mouth) 
- itrakonazol, flukonazol, ketokonazol, posakonazol ali vorikonazol (če zdravilo zaužijete ali ga prejmete z injekcijo) za zdravljenje glivičnih okužb
It is not recommended to co-administer OLYSIO with darunavir/ritonavir. 
OLYSIO z darunavirjem oziroma ritonavirjem ni priporočljiva.
The following side effects may happen with OLYSIO when used in combination with sofosbuvir: Common: may affect up to 1 in 10 people: - itching of the skin - skin rash* - constipation - being sensitive to sunlight (photosensitivity) - increased ‘bilirubin' levels in your blood (bilirubin is a pigment made by the liver). 
Pri jemanju zdravila OLYSIO skupaj s sofosbuvirjem se lahko pojavijo naslednji neželeni učinki: Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov: - srbenje kože
The company wanted the authorisation to be recognised in Belgium, Germany, Italy, Spain, Sweden and the United Kingdom (the ‘concerned Member States'). 
Družba je želela, da se dovoljenje za promet z zdravilom prizna v Belgiji, Nemčiji, Italiji, Španiji, na Švedskem in v Združenem kraljestvu (zadevne države članice).
The review was carried out under an ‘Article 29' referral1. 
Pregled je bil izveden v skladu z napotitvenim postopkom1 iz člena 29.
Dr Robert James Hemmings 
dr. Robert James Hemmings dr. Tomas Salmonson
Questions and answers on the referral for Ciclosporin IDL and associated names capsules containing ciclosporin 25 mg, 50 mg and 100 mg 
Vprašanja in odgovori v zvezi z napotitvijo za zdravilo Ciclosporin IDL in povezana imena kapsule, ki vsebujejo ciklosporin v odmerku 25 mg, 50 mg in 100 mg
Prof. Pieter de Graeff 
prof. Pieter de Graeff dr. Ondřej Slanař
However, because the concerned Member States were not able to reach an agreement, the Dutch medicines regulatory agency referred the matter to the CHMP for arbitration on 2 December 2008. 
Ker pa zadevne države članice niso dosegle soglasja, je nizozemski regulatorni organ 2. decembra 2008 zadevo napotil na CHMP v arbitražo.
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP was of the opinion that bioequivalence between Ciclosporin IDL and the reference medicine had not been sufficiently demonstrated. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave v okviru Odbora je CHMP menil, da biološka enakovrednost med zdravilom Ciclosporin IDL in referenčnim zdravilom ni bila zadostno dokazana.
Ciclosporin IDL is a generic medicine that is based on a reference medicine authorised in Germany (Sandimmun Optoral 25 mg capsules). 
Zdravilo Ciclosporin IDL je generično zdravilo, ki temelji na referenčnem zdravilu, odobrenem v Nemčiji (Sandimmun Optoral 25 mg kapsule).
An autoimmune disease is a disease which is caused by the body's own defence system attacking normal tissue, such as psoriasis (a disease causing red, scaly patches on the skin), atopic dermatitis (eczema, an itchy red rash), nephrotic syndrome (a kidney disease) and rheumatoid arthritis (inflammation of the joints). 
Avtoimunska bolezen je bolezen, ki jo povzroča obrambni sistem telesa, ki napade normalno tkivo, kot so psoriaza (bolezen, ki povzroča rdeče, luskaste zaplate na koži), atopični dermatitis (ekcem, srbeč rdeč izpuščaj), nefrotski sindrom (obolenje ledvic) in revmatoidni artritis (vnetje sklepov).
London, 23 April 2009 Doc. 
London, 22 julija 2010 Ref. dok.
It is used in patients who have had a transplant, to prevent rejection (when the immune system attacks the transplanted organ). 
Uporablja se pri bolnikih, pri katerih je bila opravljena presaditev, za preprečevanje zavrnitve presadka (ko imunski sistem napade presajeni organ).
In addition the Committee has also recommended that the marketing authorisation for Ciclosporin IDL in the Netherlands and other member states in the EU where the product has been authorised should be suspended until satisfactory bioequivalence data are obtained. 
Poleg tega je Odbor priporočil, da je treba dovoljenje za promet z zdravilom Ciclosporin IDL na Nizozemskem in v drugih državah članicah EU, v katerih je zdravilo pridobilo dovoljenje za promet, začasno umakniti, dokler ne bodo na voljo zadostni podatki o biološki enakovrednosti.
Why was Ciclosporin IDL reviewed? 
Zakaj je bilo zdravilo Ciclosporin IDL pregledano?
It is also used to treat or prevent graft-versus-host disease (when the immune system of the transplanted organ attacks the patient's tissues). 
Uporablja se tudi za zdravljenje ali preprečevanje bolezni presadka proti gostitelju (ko imunski sistem presajenega organa napade bolnikova tkiva).
The company International Drug Licensing (IDL) submitted Ciclosporin IDL for mutual recognition on the basis of the initial authorisation granted by the Netherlands on 10 August 2007. 
Družba International Drug Licensing (IDL) je dne 10. avgusta 2007 predložila vlogo za medsebojno priznavanje zdravila Ciclosporin IDL na podlagi prvotnega dovoljenja za promet, odobrenega na Nizozemskem.
The grounds for the referral were that five of the concerned Member States did not agree that enough evidence had been presented to show that Ciclosporin IDL was ‘bioequivalent' to the reference medicine. 
Podlaga za napotitev je bila, ker se pet zadevnih držav članic ni strinjalo, da so bili predloženi zadostni dokazi o biološki enakovrednosti zdravila Ciclosporin IDL referenčnemu zdravilu.
Ciclosporin IDL is also used to treat autoimmune diseases. 
Zdravilo Ciclosporin IDL se uporablja tudi za zdravljenje avtoimunskih bolezni.
What is Ciclosporin IDL? 
Kaj je zdravilo Ciclosporin IDL?
The CHMP therefore concluded that the benefits of Ciclosporin IDL do not outweigh its risks, and that the marketing authorisation should not be granted in the concerned Member States. 
CHMP je zato zaključil, da koristi zdravila Ciclosporin IDL ne odtehtajo z njim povezanih tveganj, in priporočil, da se dovoljenje za promet z zdravilom v zadevnih državah članicah ne odobri.
It acts on some special cells in the immune system called T-cells that are responsible for attacking transplanted organs or, in auto-immune diseases, normal tissue. 
Zdravilna učinkovina zdravila Ciclosporin IDL, ciklosporin, deluje na nekatere posebne celice v imunskem sistemu, imenovane celice T, ki so odgovorne za to, da napadajo presajene organe ali, pri avtoimunskih boleznih, normalno tkivo.
The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Ciclosporin IDL. 
Evropska agencija za zdravila je 23. aprila 2009 po nesoglasju med državami članicami Evropske unije (EU) glede odobritve zdravila Ciclosporin IDL zaključila arbitražni postopek.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Ciclosporin IDL do not outweigh its risks, and that the marketing authorisation granted in the Netherlands cannot be recognised in other Member States of the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da koristi zdravila Ciclosporin IDL ne odtehtajo njegovih tveganj ter da se dovoljenje za promet z zdravilom, odobreno na Nizozemskem, ne more priznati v drugih državah članicah EU in da je treba zato dovoljenje za promet z zdravilom na Nizozemskem začasno umakniti.
Company responses provided on: 16 January 2009 Opinion date: 
Odgovori družbe, poslani dne:
18 December 2008 
Datum začetka napotitvenega posto 18. december 2008
Ciclosporin IDL is an immunosuppressive medicine. 
Ciclosporin IDL je imunosupresivno zdravilo (zdravilo, ki zmanjšuje delovanje imunskega sistema, tj. naravne obrambe telesa).
A European Commission decision on this opinion will be issued in due course. 
Evropska komisija je odločbo izdala 22. julija 2010.
The active substance in Ciclosporin IDL, ciclosporin, is an immunosuppressive agent. 
Družba International Drug Licensing, ki trži zdravilo Ciclosporin IDL, je zahtevala ponovno presojo mnenja.
2 protective mats 
2 zaščitni podlogi
Powder: 500 U; Solvent: 5 ml 
prašek: 500 U; vehikel: 5 ml
Intravenous use powder: vial (glass); solvent: vial (glass) 
500 U prašek in vehikel za raztopino za injiciranje intravenska uporaba prašek: viala (steklo); vehikel: viala (steklo)
2 powder vials 2 solvent vials 2 filter transfer devices 
2 viali s praškom 2 viali z vehiklom 2 pripravi za prenos s filtrom 2 10 ml brizgi za enkratno uporabo 2 kompleta za punkcijo vene
It may be used: 
Uporablja se lahko:
This summary was last updated in September 2019. 
Povzetek je bil nazadnje posodobljen septembra 2019.
The veterinarian will decide if additional treatment is needed. 
Veterinar bo presodil, ali je potrebno kakršno koli dodatno zdravljenje.
Further information on Bravecto can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/bravecto. 
Nadaljnje informacije o zdravilu Bravecto so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/bravecto.
Bravecto received a marketing authorisation valid throughout the EU on 11 February 2014. 
Zdravilo Bravecto je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 11. februarja 2014.
Other information about Bravecto 
Druge informacije o zdravilu Bravecto
The European Medicines Agency decided that Bravecto's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je odločila, da so koristi zdravila Bravecto večje od z njim povezanih tveganj, in da se lahko odobri za uporabo v EU.
People handling the medicine should not smoke, eat or drink and should wash their hands thoroughly after handling the product. 
Osebe med uporabo zdravila ne smejo kaditi, jesti ali piti in si morajo po uporabi zdravila temeljito umiti roke.
What is Bravecto and what is it used for? 
Kaj je zdravilo Bravecto in za kaj se uporablja?
What are the risks associated with Bravecto? 
Kakšna tveganja so povezana z zdravilom Bravecto?
Used pipettes should be disposed of immediately. 
Uporabljene merilne kapalke je treba nemudoma zavreči.
What benefits of Bravecto have been shown in studies? 
Kakšne koristi je zdravilo Bravecto izkazalo v študijah?
In case of eye contact, the affected area should be rinsed immediately with water. 
V primeru stika z očmi je treba prizadeto področje nemudoma izprati z vodo.
It blocks the normal movement of charged chloride particles (ions) in and out of nerve cells, especially those associated with gamma-aminobutyric acid (GABA) and glutamate, two substances that convey messages between nerves (neurotransmitters). 
Zavira normalno prehajanje nabitih kloridnih delcev (ionov) v živčne celice in iz njih, in sicer zlasti tistih, ki so povezani z gama-aminomasleno kislino (GABA) in glutamatom, tj. dvema snovema, ki prenašata sporočila med živci (živčna prenašalca).
An overview of Bravecto and why it is authorised in the EU 
Pregled zdravila Bravecto in zakaj je odobreno v EU
Why is Bravecto authorised in the EU? 
Zakaj je zdravilo Bravecto odobreno v EU?
For ear mite infestations, a veterinary check is advised 28 days after treatment. 
Za zdravljenje infestacij z ušesnimi garjami je priporočljiv veterinarski pregled 28 dni po zdravljenju.
Contact with skin and/or eyes should be avoided including hand to eye contact. 
Treba se je izogibati stiku s kožo in/ali očmi ter dotiku oči z rokami.
This means that it kills parasites that live on or in the skin or in the fur or ears of animals, such as fleas, ticks and mites. 
To pomeni, da uničuje zajedavce, ki živijo na koži ali v njej ali v dlaki ali ušesih živali, kot so bolhe, klopi in garjavci.
The product should be kept in the original package until use, in order to prevent children directly accessing the medicine. 
Do uporabe ga je treba shranjevati v originalni ovojnini, da se otrokom prepreči neposreden stik z njim.
The effectiveness of Bravecto against fleas and ticks was investigated in both laboratory and field studies. 
Učinkovitost zdravila Bravecto proti bolham in klopom so proučevali v laboratorijskih in terenskih študijah.
The main measure of effectiveness was the reduction in the number of fleas and ticks in the infested dogs during the 3 months after receiving treatment. 
Glavno merilo učinkovitosti je bilo zmanjšanje števila bolh in klopov na infestiranih psih v treh mesecih po dajanju zdravila.
For optimal tick control, treatment should be repeated every 8 to 12 weeks depending on the tick species. 
Za optimalen nadzor nad klopi je treba zdravljenje ponoviti vsakih osem do 12 tednov, odvisno od vrste klopov.
Fluralaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs' or cats' environment. 
Fluralaner uniči bolhe, preden izležejo jajčeca, s čimer pomaga zmanjšati kontaminacijo okolice psa ali mačke.
Fluralaner kills fleas, ticks and mites that have ingested the dog's or cat's blood by acting on their nervous system. 
Fluralaner uniči bolhe, klope in garjavce, ki so zaužili kri psa ali mačke, tako da deluje na njihov živčni sistem.
The active substance in Bravecto, fluralaner, acts as an ‘ectoparasiticide'. 
Učinkovina v zdravilu Bravecto, fluralaner, deluje kot ektoparaziticid.
For more information about using Bravecto, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila Bravecto glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
Because parasites must start feeding on the dog or cat in order to be killed by the medicine, they might still be able to transmit any diseases with which they may be infected. 
Ker lahko zdravilo parazite uniči šele potem, ko se začnejo hraniti s krvjo psa ali mačke, še vedno obstaja možnost prenosa bolezni, s katerimi so morda okuženi.
Bravecto contains the active substance fluralaner. 
Zdravilo Bravecto vsebuje učinkovino fluralaner.
How does Bravecto work? 
Kako zdravilo Bravecto deluje?
Bravecto was effective against fleas and ticks for up to 12 weeks after treatment, and was as effective as fipronil in terms of the percentage of dogs and cats as well as households free of fleas and ticks. 
Zdravilo Bravecto je bilo učinkovito proti bolham in klopom do 12 tednov po zdravljenju in je bilo enako učinkovito kot fipronil z vidika deleža psov in mačk ter gospodinjstev brez bolh in klopov.
Bravecto spot-on solution should be kept away from heat, sparks, open flames or other fire sources as it is highly flammable. 
Zdravilo Bravecto v obliki raztopine za kožni nanos je treba hraniti ločeno od vročine, isker, odprtega ognja ali drugih virov vžiga, saj je zelo vnetljivo.
This product is harmful if swallowed. 
Zdravilo je škodljivo pri zaužitju.
• as part of the management of flea allergy dermatitis (an allergic reaction to flea bites) in dogs and cats 
• kot del obvladovanja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh) pri mačkah in psih;
For dogs, several spots may be applied from the initial spot in a line to the base of the tail. 
Pri psih se lahko nanese na več mest, in sicer od mesta prvotnega nanosa v smeri proti korenu repa.
It takes up to 48 hours for the application site to become dry but it will be noticeable for longer. 
Da se mesto nanosa posuši, traja do 48 ur, opazno pa je še dlje časa.
For the full list of all side effects reported with Bravecto, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Bravecto, glejte navodilo za uporabo.
In cats, Bravecto kills fleas within 12 hours and ticks within 48 hours. 
Pri mačkah zdravilo bolhe uniči v 12 urah in klope v 48 urah.
Bravecto is a veterinary medicine used to treat parasitic infestations in dogs and cats. 
Zdravilo Bravecto je zdravilo, ki se uporablja v veterinarski medicini za zdravljenje infestacij s paraziti pri psih in mačkah.
The most common side effects of the tablets in dogs (which may affect more than 1 in 100 animals) are mild and short-lived diarrhoea, vomiting, lack of appetite and drooling. 
Najpogostejši neželeni učinki tablet pri psih (ki lahko prizadenejo več kot 1 žival od 100) so blaga in prehodna driska, bruhanje, pomanjkanje teka in slinjenje.
In order to be exposed to the active substance, parasites must attach to the skin and commence feeding on the dog or cat. 
Da bi bili paraziti izpostavljeni učinkovini, se morajo pritrditi na kožo ter začeti hraniti s krvjo psa ali mačke.
Bravecto spot-on solution and the wet skin of a recently treated animal may be slightly irritating to skin and/or eyes. 
Zdravilo Bravecto v obliki raztopine za kožni nanos in vlažna koža živali, ki je pred kratkim prejela zdravilo, sta lahko rahlo dražilna za kožo in/ali oči.